The prevalent and debilitating functional bowel disorder, irritable bowel syndrome (IBS), is characterized by symptoms that include abdominal pain, bloating, diarrhoea and/or constipation.
IRRITABLE BOWEL SYNDROME
Irritable bowel syndrome is a common and debilitating gastrointestinal (GI) disorder characterized by episodic exacerbations of a cluster of symptoms, which include heightened central pain sensitivity, bloating, diarrhoea and/or constipation (Enck et al., 2016) . This functional bowel disorder has a high prevalence and may significantly impair the quality of life of sufferers. Diagnosis is symptom based, and this is made more difficult by the degree of heterogeneity in the patient population. Risk factors for the development of this multifactorial disorder include being female (Lovell & Ford, 2012) , having a family history of IBS (Saito & Talley, 2008) , childhood trauma (Dinan, Cryan, Shanahan, Keeling, & Quigley, 2010) and/or prior GI infection (Schwille-Kiuntke, Frick, Zanger, & Enck, 2011; Thabane, Kottachchi, & Marshall, 2007) .
Consistent with a role for immune activation in this disorder, elevated numbers of mucosal T cells, lymphocytes and mast cells (Chadwick et al., 2002) are noted in IBS patients. Circulating pro-inflammatory c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society cytokine profiles are also different in IBS patients compared with healthy control subjects (Dinan et al., 2006; Liebregts et al., 2007) .
However, pre-morbid psychological conditions increase the likelihood of developing IBS after infectious gastroenteritis (Thabane et al., 2007) . Co-morbidity with mood disorders, such as depression and anxiety, is more common in IBS patients (Fond et al., 2014) , and a maladaptive stress response, mediated by the hypothalamicpituitary-adrenal (HPA) axis, is key to the initiation, severity and persistence of IBS-associated symptom flare-ups (Dinan et al., 2006) . Indeed, psychosocial and infection-related stresses are additional considerations in comprehending the chronic relapsing pattern that typifies IBS symptoms (O'Malley, 2015; O'Malley, Quigley, Dinan, & Cryan, 2011) . Given that glucagon-like peptide (GLP)-1 mimetics have been found to alleviate acute pain symptoms in IBS patients (Hellstrom et al., 2009; Li et al., 2017) , GLP-1 may be important in the manifestation of IBS symptoms. In this review, I assess the evidence currently available to support a role for GLP-1-secreting L-cells in the Experimental Physiology. 2019;104:3-10.
wileyonlinelibrary.com/journal/eph 3 pathophysiology of IBS. Moreover, the potential importance of the Lcell as a signal transducer pivotal to cross-barrier communication, from the luminal microbiome to the gut and on to the brain, is reviewed.
SYMPTOM MANIFESTATION IN SUBTYPES OF IRRITABLE BOWEL SYNDROME PATIENTS
Irritable bowel syndrome symptoms manifest as bloating, visceral pain and altered bowel habit. Subtypes include diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C) or alternating/mixed IBS phenotypes (IBS-A/IBS-M) (Longstreth et al., 2006) . The distribution of these subtypes varies depending on the diagnostic criteria used, the populations evaluated and the geographical location of the study (Guilera, Balboa, & Mearin, 2005; Hungin et al., 2005; Kibune Nagasako, Garcia Montes, Silva Lorena, & Mesquita, 2016 
POSTPRANDIAL EXACERBATION OF IRRITABLE BOWEL SYNDROME SYMPTOMS
A commonly reported feature of IBS is postprandial exacerbation of GI symptoms. Many IBS patients experience diarrhoea, flatus, bloating and abdominal pain after ingestion of a meal. Particular food types, such as milk, pulses, wheat and apples, which are rich sources of poorly absorbed short-chain carbohydrates, are associated with IBS symptom exacerbation (Cabre, 2010; Morcos, Dinan, & Quigley, 2009; Ragnarsson & Bodemar, 1998) , an effect that is unrelated to IBS subtype or GI-specific anxiety, depression, body mass index or age (Böhn, Störsrud, Törnblom, Bengtsson, & Simrén, 2013 This review explores the potential role for L-cells in these pathophysiological changes.
• What advances does it highlight?
L-cells, which secrete glucagon-like peptide-1 in response to nutrients, microbial factors, bile acids and shortchain fatty acids, may sense IBS-related changes in the luminal environment. Glucagon-like peptide-1 can act as a hormone, a paracrine factor or a neuromodulatory factor and, through its actions on central or peripheral neurons, may play a role in gastrointestinal dysfunction.
some success in managing IBS symptoms (Halmos, Power, Shepherd, Gibson, & Muir, 2014; Marsh, Eslick, & Eslick, 2016; Staudacher et al., 2012) , although not everyone supports this conclusion (Peters et al., 2016; Rao, Yu, & Fedewa, 2015) . A low-FODMAP dietary intervention suppresses production of total short-chain fatty acids (SCFAs) (Hustoft et al., 2017) , which are increased in IBS patients and linked to symptoms such as visceral hypersensitivity and altered contractile activity (Ford et al., 2014) . Glucagon-like peptide-1-secreting enteroendocrine L-cells embedded in the epithelium of the distal gut, where the highest density of microbes is found, express receptors for SCFAs (Tolhurst et al., 2012) .
INTESTINAL GLUCAGON-LIKE PEPTIDE-1-SECRETING L-CELLS
Glucagon-like peptide-1 has a well-characterized role in stimulating pancreatic insulin synthesis, but also has additional functions as a gut regulatory compound (Hellstrom, 2011) . GLP-1, a 30-aminoacid peptide derived from the post-translational processing of preproglucagon, is secreted basolaterally by L-cells. The L-cells are electrically excitable biosensors (Chimerel et al., 2014) , which sense the arrival of nutrients, such as glucose and amino acids, in the small intestine (Drucker, Habener, & Holst, 2017; Elliott et al., 1993) . Chemosensory activation of L-cells results in membrane depolarization, action potential firing and the opening of voltage-gated calcium channels. This subsequently causes enhanced rates of vesicular exocytosis on the basolateral surface of the epithelial barrier (Reimann & Gribble, 2016) . This is consistent with a peak in circulating GLP-1 within 15 min of food intake. However, despite the reduced probability of nutrients being present there, the abundance of GLP-1-secreting Lcells increases towards the distal end of the GI tract (Steinert et al., 2017) . Moreover, the time it would take for nutrients to reach the distal gut exceeds the circulating GLP-1 peak. This suggests that L-cells in the small intestine and the colon have different functions in terms of the moieties they sense (Greiner & Backhed, 2016) . Glucose and amino acids activate small intestinal L-cells, whereas colonic L-cells express receptors for SCFAs and bile acids (Reimann et al., 2008; Tolhurst et al., 2012) . Given its short half-life in the circulation, it is likely that GLP-1, in addition to its classical endocrine function, works through paracrine mechanisms.
GLUCAGON-LIKE PEPTIDE-1 MODULATES GASTROINTESTINAL FUNCTION
Irritable bowel syndrome is characterized by altered motility and absorpto-secretory function, which may be centrally or peripherally orchestrated. In a placebo-controlled double-blind crossover clinical trial, in which a synthetic GLP-1 analogue, ROSE-010, was administered to a mixed group of 99 IBS patients, anti-spasmodic and pain-relieving properties were reported (Hellstrom et al., 2009 ). ROSE-010 appeared to be most effective in IBS-A subtypes in this trial. In a more recent study, the potential mechanism underlying the beneficial effects of the GLP-1 mimetic on abdominal pain in IBS-C patients was investigated. Decreased circulating GLP-1 concentrations and decreased mucosal expression of GLP-1Rs were associated with constipation-predominant IBS. Moreover, this was correlated with the severity of abdominal pain (Li et al., 2017) . The authors suggested that lower GLP-1 led to loss of the pro-kinetic effects of GLP-1 in the colon (Camilleri et al., 2012) , resulting in constipation and abdominal pain (Li et al., 2017) . Consistent with the supposition that decreased GLP-1 contributes to pain-related symptoms, circulating levels of bioactive GLP-1 were also decreased in a rat model of visceral pain sensitivity (Yang et al., 2014) .
Biologically active GLP-1 has a high affinity for GLP-1 receptors (Reimann et al., 2008) , which are expressed in vagal ganglia (Richards et al., 2014) and in brain regions such as the nucleus tractus solitarius, the ventrolateral medulla (Lim et al., 2009 ) and the hypothalamus (Richards et al., 2014) . GLP-1 receptors have also been detected in both the myenteric and the submucosal neuronal plexi in the GI tract (Amato et al., 2010; Kedees, Guz, Grigoryan, & Teitelman, 2013) , which are the neural regulators of gut contractile activity and absorptosecretory function, respectively. In the upper part of the GI tract, GLP-1 appears to have a mollifying effect on gut function. Using vagal neural pathways, GLP-1 has been shown to delay gastric emptying (Imeryüz et al., 1997) and small intestinal secretion (Baldassano, Wang, Mule, & Wood, 2011) and motility (Nauck et al., 2011) . GLP-1 also inhibits postprandial motility in the antrum, jejunum and duodenum through direct actions on myenteric neurons (Halim et al., 2018) . 
GLUCAGON-LIKE PEPTIDE-1-MEDIATED MODIFICATION OF THE STRESS AXIS
Crosstalk between GLP-1 and the stress hormone, corticotrophinreleasing factor (CRF), which initiates the HPA signalling axis and is a central tenet in bowel dysfunction in IBS pathology ( 
L-CELLS AS CHEMOSENSORS FOR AN ALTERED LUMINAL ENVIRONMENT IN IRRITABLE BOWEL SYNDROME?
Many studies have demonstrated that changes in the gut microbiome, including reduced bacterial diversity and increased temporal instability, are factors worthy of consideration in understanding IBS pathophysiology (Salem, Singh, Ayoub, Khairy, & Mullin, 2018) .
Evidence supporting the importance of the microbiome in functional bowel disorders comes from studies demonstrating the benefits of specific commensal strains in alleviating IBS symptoms (Tiequn, Guanqun, & Shuo, 2015; Yuan et al., 2017) . Moreover, microbial dysbiosis in IBS (Liu et al., 2017) has been implicated in enhanced gut permeability (Simren et al., 2013) , visceral hypersensitivity (Crouzet et al., 2013; Valdez-Morales et al., 2013) and altered GI motility (Cani, Everard, & Duparc, 2013; Gudsoorkar & Quigley, 2014) . The 
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Furthermore, specific commensal strains increased intestinal and circulating GLP-1 (Aoki et al., 2017; Stenman et al., 2015) . Somewhat counter-intuitively, germ-free mice also exhibit increased serum GLP-1 (Selwyn, Csanaky, Zhang, & Klaassen, 2015) , although another study found that germ-free mice exhibited a strong state of GLP-1 resistance, with impaired GLP-1-evoked gut-brain signalling and enteric nervous system function (Grasset et al., 2017) . GLP-1 concentrations also increase after dietary supplementation with fermentable fibre (Massimino et al., 1998) , which is converted to SCFAs (acetate, propionate and butyrate), molecules known to activate L-cells and induce GLP-1 secretion (Nøhr et al., 2013; Tolhurst et al., 2012) . L-cells also express receptors for bile acids (Brighton et al., 2015) , and the bile acid pool is altered in IBS patients (Mosinska, Szczepaniak, & Fichna, 2018) .
THE NEUROMODULATORY ACTIONS OF GLUCAGON-LIKE PEPTIDE-1
Beneath the epithelium lies a complex network of intrinsic and extrinsic neurons, including spinal nerves and the vagus nerve, which innervates most of the GI tract and is composed of between 70 and 80% afferent nerves (Prechtl & Powley, 1990) . The vagus has been implicated in the actions of specific probiotic strains on central cognitive processes (Bercik et al., 2011; Bravo et al., 2011; PerezBurgos et al., 2013) , and some bacterial products are capable of signalling across the mucosal barrier to stimulate vagus nerve firing (Buckley & O'Malley, 2018; Perez-Burgos et al., 2013) . Lipophilic molecules, such as SCFAs, can directly activate afferent terminals (Lal, Kirkup, Brunsden, Thompson, & Grundy, 2001 ), but many luminal proteins are large and complex protein microbial molecules (Forsythe et al., 2014) , which cannot cross the barrier passively. Sensory nerve fibres terminate below the epithelial layer and do not reach through to the lumen. Although infiltration of bacterial products via a leaky epithelium may occur in disorders such as IBS, physiological mechanisms of informing the CNS about the luminal environment are also likely to exist. Indeed, as previously mentioned, the microbiota can induce modification of gut function through the stimulation of serotonin secretion (Yano et al., 2015) . L-cells are also activated by the bacterial metabolite indole, which inhibits voltage-gated K + channels, resulting in cellular depolarization and sustained secretion of GLP-1 (Chimerel et al., 2014) . Evidence of direct, physical contact between a pseudopod-like elongation of L-cells and efferent and afferent nerves (Bohorquez et al., 2015) indicates a neurally mediated mechanism by which L-cell activation could modify GI function. Indeed, GLP-1 has direct neurostimulatory actions on the vagus (McKee & Quigley, 1993) through activation of GLP-1 receptors on vagal afferents (Nakagawa et al., 2004; Ronveaux, de Lartigue, & Raybould, 2014) . Thus, L-cells are appropriately positioned to facilitate cross-barrier signalling from the gut lumen to the host peripheral nervous system and on to the CNS. Although neuroendocrine signalling has been implicated in IBS (El-Salhy et al., 2012) , it has yet to be demonstrated conclusively that the chemosensory actions of L-cells detecting changes in the luminal micro-environment contribute to altered bowel function.
CONCLUSIONS
Irritable bowel syndrome is a prevalent and debilitating functional bowel disorder that is characterized by increased sensitivity to visceral pain and altered bowel habit. In addition to alterations in 
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